Panagora Asset Management Inc., a leading investment management firm, has significantly increased its stake in LivaNova PLC, according to the company’s recent filing with the Securities and Exchange Commission. During the first quarter of this year, Panagora Asset Management Inc. boosted its position in LivaNova shares by an impressive 474.9%. The firm now owns 224,945 shares of LivaNova stock, an increase of 185,816 shares from the previous period. This translates to a 0.42% ownership stake in LivaNova, which is valued at $9,803,000 as of the end of the most recent quarter.
LivaNova, listed on the NASDAQ under the ticker symbol LIVN, recently released its quarterly earnings results on July 26th. The company reported earnings per share (EPS) of $0.78 for the quarter, surpassing market expectations by $0.24 per share. Analysts had predicted an EPS of just $0.54 for LivaNova during this period. Furthermore, LivaNova generated revenue of $293.90 million for the quarter, marking a significant increase compared to analyst estimates of $265.05 million. This represents a remarkable revenue growth rate of 15.6% when compared to the same quarter last year.
Additionally, LivaNova demonstrated positive performance indicators during this quarter’s financial report as it boasted a return on equity (ROE) of 11.60%. However, it is worth noting that its net margin was negative at -8.94%. Despite this setback in profitability, LivaNova displayed considerable overall financial improvement and outperformed its previous year’s earnings-per-share figure of $0.53.
LivaNova PLC operates as a medical device company that designs innovative therapeutic solutions for patients worldwide across three key segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment focuses on the development, production, and sale of various cardiopulmonary products including heart-lung machines, oxygenators, perfusion tubing systems, autotransfusion systems, and related devices.
As the healthcare industry continues to evolve and demand for medical devices grows globally, LivaNova is well-positioned to capitalize on these opportunities. With its commitment to innovation and a strong product portfolio, the company is expected to post strong financial performance for the current fiscal year. Analysts predict that LivaNova PLC will achieve earnings per share (EPS) of 2.39 by the end of this year.
In conclusion, Panagora Asset Management Inc.’s significant increase in its position within LivaNova PLC highlights confidence in the company’s future prospects. LivaNova’s impressive quarterly earnings results and consistent revenue growth underscore its ability to deliver value to shareholders. As a leading player in the medical device industry with a commitment to therapeutic solutions, LivaNova is poised for continued success in meeting the evolving healthcare needs of patients worldwide.
[bs_slider_forecast ticker=”LIVN”]
LivaNova Attracts Institutional Investors and Hedge Funds, Poised for Growth in the Medical Technology Industry
LivaNova, a medical technology company specializing in cardiac surgery and neuromodulation solutions, has recently gained attention from institutional investors and hedge funds. Bank of America Corp DE significantly increased its stake in LivaNova by 38.5% during the fourth quarter, acquiring an additional 293,118 shares and bringing their total ownership to 1,055,298 shares valued at $58,611,000. Similarly, Principal Financial Group Inc. raised its stake in LivaNova by 1.8% during the same period, adding 4,003 shares to reach a total of 221,118 shares worth $12,281,000.
The interest in LivaNova has also extended to Guggenheim Capital LLC and Y Intercept Hong Kong Ltd. Guggenheim Capital LLC recorded an astounding increase in their holdings of LivaNova by 1,016.5% during the first quarter. They acquired an additional 111,770 shares that boosted their overall ownership to 122,766 shares valued at $5,350,000. Meanwhile, Y Intercept Hong Kong Ltd made a new investment in LivaNova during the first quarter with a value of approximately $529,000.
In addition to these institutional investors’ activities with LivaNova’s stock, Van ECK Associates Corp purchased a new position worth about $430,000 in the company’s stock during the fourth quarter.
When it comes to overall ownership of LivaNova’s stock among institutional investors and hedge funds as a whole group narrative is dominant: they command an impressive 97.64% control over the company’s stock.
On Friday morning (September 3), shares of LivaNova opened at $55.55. As of now (reference date September 3rd), the market capitalization for the company stands at $2.99 billion with a price-to-earnings ratio of -30.52 and a beta of 0.91. LivaNova’s stock has experienced a range of values in the past year, reaching as low as $40.26 and as high as $62.80.
Technical indicators for LivaNova suggest that the stock has demonstrated resilience in recent times. The 50-day simple moving average stands at $54.06, while the two-hundred-day simple moving average is slightly lower at $49.09. These values indicate an upward trend for LivaNova’s stock performance.
Several analysts have recently issued reports on LivaNova, providing insights into the company’s prospects. StockNews.com began coverage on LivaNova with a “buy” rating on August 17th, expressing optimism about the future potential of the company’s stock.
TheStreet also upgraded its rating on LivaNova from a “d+” to a “c-” in July, indicating signs of improvement and growth within the organization.
In line with this positive outlook, Robert W. Baird lifted their target price for LivaNova shares from $56.00 to $62.00 in late July, further highlighting their confidence in the company’s trajectory.
Mizuho raised their price target for LivaNova from $53.00 to $60.00 around the same time period, affirming their belief in the upward momentum of the stock.
Barclays also increased their price objective for LivaNova shares from $51.00 to $57.00 while maintaining an “equal weight” rating on the stock in July.
According to Bloomberg.com, which aggregates these various analyst reports, LivaNova currently holds a consensus rating of “Moderate Buy.” The average target price for LivaNova shares is estimated at $67.17.
In conclusion, institutional investors and hedge funds have been avidly investing in LivaNova’s stock recently due to its promising potential within the medical technology industry. This surge in interest, combined with positive analyst reports and the company’s favorable technical indicators, suggests that LivaNova is poised for future growth and success.
